Top
Summary and Future Directions
Ozone, an allotropic form of oxygen, possesses unique properties which are being defined and applied to biological systems as well as to clinical practice. As a molecule containing a large excess of energy, through incompletely understood mechanisms, it manifests bactericidal, virucidal and fungicidal action which may make it a treatment of choice in certain conditions and an adjunct to treatment in others. Although ozone's medicinal effects were discovered in the 19th century and clinically applied during World War I, equipment capable of purity and reliability of delivery of oxygen-ozone mixtures were not available until the late 1950s. Since then, experience has accumulated for the administration of ozone to humans and animals via a variety of routes, in doses that are both nontoxic and relevant to clinical problems, externally in gaseous form (or in solution) and systemically in blood ozonation.
A review of a large body of literature is presented which describes a spectrum of therapeutic indications. Of these, ozone application for superficial infection, burns, dental and intestinal conditions, and possibly circulatory problems seem to be the most promising. As regards blood ozonation, further research is indicated to delineate the nature of its dynamics and the extent of its effectiveness in (1) the identification of the galaxy of compounds formed in this process which, in view of doses administered, by all evidence, have metabolic, immunological, endocrine and possibly neurological effects; (2) the purification of blood or blood components for transfusion purposes; (3) the inhibition of carcinomas with reference to the types which may be the most susceptible and to its use as an adjunct to radiation or chemotherapy; and (4) the inactivation or the repression of viral diseases with special attention to chronic conditions of the Herpes or Retroviridae (HIV) families.
Top
References
1. Ihde AJ: The Development of Modern Chemistry, Harper and Row, New York, 1964.
2. Partington JR: A History of Chemistry. Macmillan and Co., New York, 1962.
3. Schonbein C: Notice of C Sch., the discoverer of ozone.
Annual Report of the Board of Regents of the Smithsonian Inst., 1868, Washington, DC, US Government Printing Office, 1869, 185-192.
4. Razumovskii SD, Zaikov GE: Ozone and Its Reactions With Organic Compounds. Elsevier, New York. 1984.
5. Rilling S, Veibahn R: The Use of Ozone in Medicine. Haug, New York, 1987.
6. Payr E: Uber ozonbehandlung in der chirurgie. Munch med Wschr 1935;82:220-291.
7. Wolff H: Das Medizinische Ozon. Heidelberg, VFM Publications, 1979.
8. Hansler J, Weiss H: Beitrag zum Unterschied zwischen HOT und Ozontherapie mit dem Ozonosan Erfahr hk 1976,25:185-188.
9. Gumulka J, Smith L: Ozonation of cholesterol. J. Am Chem Soc 1983;105(7): 1972-1979.
10. Smith LL: Cholesterol autoxidation of lipids. Chemistry and Physics of Lipids. 1987;44:87-125.
11. Meadows J, Smith R: Uric acid protection of nucleobases from ozone induced degradation. Arch Biochem Biophys 1986;246(2): 838-845.
12. Menzel D: Ozone: An overview of its toxicity in man and animals. Toxicol and Environ Health 1984;13:183-204.
13. Wolff A: Eine medizinische verwendbarkeit des ozons. Dtsch Med Wschr 1915;311.
14. Held P: Verbrennungen: OzoNachrichten 1983;2:84.
15. Werkmeister H: Subatmospheric 02/03 treatment of therapy-resistant wounds and ulcerations. OzoNachrichten 1985;4:53-59.
16. Aubourg P: L'ozone medical: Production, posologie, modes d'applications cliniques. Bull Med Soc Med Paris 1938;52:745-749.
17. Medical World News. Nov. 9, 1987.
18. Vogelsberger W, Herget H: Klinische ozonanwendung. OzoNachrichten 1983;2:1.
19. Rilling S: The basic clinical applications of ozone therapy.
Ozonachrichten 1985; 4:7-17.
20. Rokitansky O: Klinik und biochemie der ozon therapy. Hospitals 1982;52:643 nd 711.
21. Wolff H: Aktuelles in der ozontherapy. Erfarhr hk 1977;26:193-196.
22. Riva-Sanseverino E: The influence of ozone therapy on the remineralization of the bone tissue in osteoporosis.
OzoNachrichten 1987;6:75-79.
23. Tietz C: ozontherapie als adjuvans in der onkologie.
OzoNachrichten 1983;2:4.
24. Washuttl J, Steiner I, Szalay S: Untersuchungen uber dieauswirkungen von ozon auf verschiedene biochemische parameter bie blutproben in vitr Erfahr hk 1979; 28:766.
25. Lacoste: Traitement des insuffisances vascuilaires pa l'ozone. Gaz med de France 1951;315 (Ref. Petersen, Med Kl 53;1958:2078.
26. Varro J: Die krebsbehandlung mit ozon. Erfahr hk 1974;23:178-181.
27. Zabel W: Ganzheitsbehandlung der gaschwulsterkrankungen.
Hippokrates 1960;3 1:751-760.
28. Turk R: Ozone in dental medicine. Ozonachrichten 1985;4:61-65.
29. Schulz S: Ozonisiertes olivenol-experimentelle ergbnisse der wundheilung am tiermodell. OzoNachrichen 1982;1:29.
30. Washuttl J, Viebahn R: ozonisiertes olivenolozusammensetzung und desinfizierence wirksamkeit. OzoNachrichen 1982;1:25.
31. Wehrli R: Transact six. Ham 1957;318.
32. Mittler S, King M, Burkhardt B: Toxicity of ozone. AMA Arch Ind Health 1957;15:191-197.
33. Clamann H: Physical and medical aspects of ozone, in Physics and Medicine of the Atmosphere and Space. John Wiley and Sons, New York, 1960, p. 151.
34. Basset D, Bowen-Kelly E: Rat lung metabolism after 3 days of continuous exposure to 0.6 parts-per-million ozone. Am J Physiol 1986;250 (2 Part 2): E131-E136.
35. McDonnell W, Horstman D, Abdul-Salaam S, House D: Reproducibility of individual responses to ozone exposure. Am Rev Respir Dis 1985;131(1): 36-40.
36. Folinsbee W: Effects of ozone exposure on lung function in man: A review. Rev Environ Health 1981;3:211-240.
37. Kulle TJ, Sauder LR, Hebel JK, Chatham MD: Ozone response relationships in healthy nonsmoker. Am Reu Respir Dis 1985;132(1):36-41.
38. Hackney J, Linn W, Mohler J, Colier C: Adaptation to short term respiratory effects of ozone in men exposed repeatedly. J Appl Physiol Respirat Environ Exercise Physiol 1977;43:82-85.
39. Melton CE: Effects of long term exposure to low levels of ozone: A review. Aviation, Space, and Environmental Medicine 1982;53:105-111.
40. Dyas A, Boughton B, Das B: Ozone killing action against bacterial and fungal species: Microbiological testing of a domestic ozone generator. J Clin Pathol (Lond) 1983;36(10):1102-1104.
41. Wolcott J, Zee YC, Osebold J: Exposure to ozone reduces influenza disease severity and alters distribution of influenza viral antigens in murine lungs. Appl Environ Microbiol 1982;443:723-731.
42. Buckley RD, Hackney JD, Clark K, Posin C: Ozone and human blood. Arch Environ Health 1975;30:40-43.
43. Viebahn R: The biochemical process underlying ozone therapy.
OzoNachrichten 1985;4:4:18-30.
44. Lohr A, Gratzek J: Bactericidal and paraciticidal effects of an activated air oxidant in a closed aquatic system. J Aquaric Aquat Sci 1984;4(41/2):1-8.
45. Ivanova O, Bogdanov M, Kazantseva V, et al: Ozone inactivation of enteroviruses in sewage. Vopr Virusol 1983;0(6):693-698.
46. Roy D, Wong PK, Engelbrecht RS, Chian ES: Mechanism of enteroviral inactivation by ozone. Appl Envir Microbiol 1981;41:718-723.
47. Roy D, Engelbrecht RS, Chian ES: Comparative inactivation of six enteroviruses by ozone. Am Water Works Assoc J 1982;74(12):660-664.
48. Mudd JB, Leavitt R, Ongun A, McManus T: Reaction of ozone with amino acids and proteins. Atmos Environ 1969;3:669-682.
49. Ishizaki K, Sawadaishi D, Miura K, Shinriki N: Effect of ozone on plasmid DNA of Escheria coli in situ. Water Res 1987;21(7):823-828.
50. Cech T: RNA as an enzyme. Scientific American 1986 Nov;255(5):64-76.
51. Matus V, Nikava A, Prakopava Z, Konyew S: Effect of ozone on the survivability of Candida utilis cells. Vyestsi AkadNauuk Bssr Syer Biyal Navuk 1981;0(3):49-52.
52. Matus V, Lyskova T, Sergienko I, Kustova A, Grigortsevich T, Konev V: Fungi; growth and sporulation after a single treatment of spores with ozone. Mikol Fitopatot 1982;16(5):420-423.
53. Gallo R: The AIDS virus. Scientific American 1987 Jan;256(1):46-74.
54. Riesser V, Perrich J, Silver B, McCammon J: Possible mechanimsm of poliovirus inactivation by ozone, in Forum on Ozone Disinfection. Proceedings of the International Ozone Institute. Syracuse, NY, 1977; pp. 186-192.
55. Mattassi R, Franchina A, D'Angelo F: Die Ozontherapie als Adjuvans in der Gefaspathologie. OzoNachrichten 1982;1:2.
56. Warburg O: On the origin of cancer cells. Science 1956;123:309-315.
57. De Vita V, Hellman S, Rosenberg S: Cancer Principles and Practice of Oncology, Lippincott, Philadelphia, 1985.
58. Sweet J, Kao MS, Lee D, Hagar W: Ozone selectively inhibits growth of human cancer cells. Science 1980;209:931-933.
59. Wenzel D, Morgan D: Interactions of ozone and antineoplastic drugs on rat fibroblasts and Walker rat carcinoma cells. Res Commun Chem Patho Pharmacol 1983;40(2):279-288.16.